Trial Information
An Observational Study of AvastinĀ® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Metastatic colorectal cancer with no previous systemic treatment for advanced disease
- Receiving Avastin in combination with a first-line standard of care chemotherapy
regimen
- Avastin initiated at the same time as first-line chemotherapy regimen
Exclusion Criteria:
- Investigational, non-standard of care first-line chemotherapy regimen for treatment
of metastatic colorectal cancer
- Contraindication to Avastin
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Safety (incidence of serious adverse events)
Outcome Time Frame:
1.5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study ID:
ML27971
NCT ID:
NCT01506167
Start Date:
July 2012
Completion Date:
June 2016
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms